A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-03

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as quality of life, effectiveness, and incidence of adverse events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT05811416

Relapsing-remitting Multiple Sclerosis (RRMS)

ACTIVE_NOT_RECRUITING

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058

Multiple Sclerosis

COMPLETED PHASE3

Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.

NCT05777902

Multiple Sclerosis

TERMINATED PHASE4

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

NCT05245344

Relapsing-Remitting Multiple Sclerosis (RRMS) Neuromyelitis Optica Healthy

UNKNOWN

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

NCT05319093

Fatigue Multiple Sclerosis

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with relapsing-remitting multiple sclerosis (RRMS) treated with Ozanimod

Ozanimod

Intervention Type DRUG

As per product label

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ozanimod

As per product label

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS)
* The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study
* All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed

Exclusion Criteria

* Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC)
* Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled
* Participation in any other clinical studies

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No